In accordance with the publishing schedule, BioWorld Science will not be published on Monday, Dec. 25, 2023, or Tuesday, Dec. 26, 2023.

Additional early-stage research and drug discovery news in brief, from: Can-Fite, Redhill.

Korea Institute of Science and Technology has described nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators acting as nitric oxide (NO) production inhibitors and antioxidants reported to be useful for the treatment of acute respiratory distress syndrome, chronic kidney disease, chronic obstructive pulmonary disease, kidney fibrosis, nonalcoholic fatty liver disease, viral hepatitis, Parkinson’s disease and Alzheimer’s disease.

University of Minnesota has divulged nonstructural protein 14 (NSP14) (SARS-CoV-2) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection.

Researchers at Centre Hospitalier de Université de Montréal and University of Pennsylvania have identified compounds reported to be useful for the treatment of HIV-1 infection.

Xiamen University has synthesized oligopeptides targeting β2-microglobulin (B2M) reported to be useful for the treatment of cancer and Alzheimer’s disease.

Jazz Pharmaceuticals plc has disclosed macrocyclic orexin OX2 receptor agonists reported to be useful for the treatment of hypersomnia, narcolepsy and sleep disorders.